Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination
of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal
cancer.